Sumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
13/08/2026 01:16
BRIEF-Sumitomo Pharma Co Ltd - Sumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa Aug 13 (Reuters) - Sumitomo Pharma Co Ltd 4506.T:
SUMITOMO PHARMA CO LTD: SUMITOMO PHARMA AMERICA ANNOUNCES FIRST PATIENT RECEIVES TREATMENT IN PHASE 1/2A STUDY FOR INVESTIGATIONAL THERAPY DSP-3077 FOR RETINITIS PIGMENTOSA
Source text: ID:nTStm7ea6e
Further company coverage: 4506.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)